Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:結膜・眼瞼・眼窩の腫瘍について発生頻度と病理組織学的診断を検討する。
対象と方法:2005年5月〜2017年4月の12年間に旭川医科大学病院眼科で切除または生検を施行して病理組織診断を得た結膜・眼瞼・眼窩の腫瘍91名99眼について,性別,良性・悪性の比率,発生時年齢,病理組織学的診断を後ろ向きに検討した。
結果:発生部位別の内訳は結膜71眼,眼瞼9眼,眼窩19眼であった。性別ごとの症例数は男性49名54眼,女性42名45眼であった。良性・悪性別の症例数は良性腫瘍63眼,悪性腫瘍36眼で良性腫瘍のほうが多かった。発生時年齢の平均は,59.2±20.2歳(8〜96歳),良性腫瘍では53.8±20.0歳,悪性腫瘍では69.1±15.1歳であった。病理組織学的診断は良性腫瘍では母斑,乳頭腫が多く,悪性ではMALTリンパ腫と眼表面扁平上皮新生物が多かった。
結論:今回の検討では発生部位では結膜が多かった。性差,良性・悪性の比率,発生時年齢について既報とおおむね同様の結果であった。眼部腫瘍の発生部位と種別は多岐にわたるので,適切な治療のためには病理組織学的診断が重要であると考えた。
Abstract Purpose:To evaluate the incidence and the histopathological diagnosis of conjunctival, eyelid and orbital tumors.
Subjects and Methods:A total of 99 eyes from 91 patients with conjunctiva, eyelid and orbital tumors at the Department of Ophthalmology, Asahikawa Medical University Hospital from May 2005 to April 2017 were included in this study. The patients' sex, incidence of benign or malignant legion, age at the onset of tumors and histopathologic diagnosis were investigated retrospectively.
Results:These cases consisted of 71 lesions in the conjunctiva, 9 in the eyelid, and 19 in the orbita. The number of the tumors by sex were 54 eyes in 49 males and 45 eyes in 42 females. Sixty-three(63.6%)of the tumors were benign and 36(36.3%)were malignant. The average age at the onset of tumors was 59.2±20.2(range 8-96)years. It was 53.8±20.0 years for benign tumors and 69.1±15.1 years for malignant tumors. The most common histopathologic diagnoses were nevi and papilloma for benign tumors and MALT lymphoma and ocular surface squamous neoplasia in malignant tumors.
Conclusion:The proportion of conjunctival tumors in this study was higher than was reported previously. The patients' sex, incidence of benign and malignant legions, and age were generally similar to those in previous reports. Both the lesions and the histopathological diagnoses of tumors were diverse. Because of the divergence, we consider the histopathological diagnosis to be important for the appropriate treatment of ocular tumors.
Copyright © 2018, Igaku-Shoin Ltd. All rights reserved.